Table 5 Summary of phase III clinical trials evaluating the efficacy of tandem ASCT to ASCT-RIC-Allo-SCT in the upfront setting for patients with MM

Krishnan et al. [130]. NDMM pts ≤70 y/o

710

ASCT × 2

CR: 45%

3-year PFS: 46%

3-year OS: 80%

3-year TRM: 4%

ASCT→RIC-Allo-SCT (TBI 2 Gy)

CR: 58%

3-year PFS: 43%

3-year OS: 77%

3-year TRM: 11%

Giaconne et al. [129]. NDMM pts ≤65 y/o

162

ASCT × 2

CR: 26%

Median EFS: 2.4 years

Median OS: 4.25 years

2-year TRM: 2%

ASCT→RIC-Allo-SCT (TBI 2 Gy)

CR: 55%

Median EFS: 2.8 years

Median OS: NR

2-year TRM:10%

Gahrton et al. [127]. NDMM pts <70 y/o

357

ASCT × 2

CR: 41%

8-year PFS:12%

8-year OS: 36%

3-year TRM: 3%

ASCT→RIC-Allo-SCT (Flu/TBI 2 Gy)

CR: 50%

8-year PFS: 22%

8-year OS: 49%

3-year TRM: 13%

Moreau et al. [128]. NDMM pts <65 y/o (w/ del 13 and β2-microglobulin >3 mg/l)

284

ASCT × 2 (+/− anti-IL6 antibody)

CR: 38%

Median EFS: 22 mos

Median OS: 48 mos

5-year TRM: N/A

ASCT→RIC-Allo-SCT (Flu/Bu)

CR: 62%

Median EFS: 19 mos

Median OS: 34 mos

5-year TRM: 11%

Rosinol et al. [126]. NDMM pts <70 y/o

752

ASCT × 2

CR: 11%

Median PFS: 31 mos

Median OS: 58 mos

TRM: 5%

ASCT→RIC-Allo-SCT (Flu/Mel)

CR: 40%

Median PFS: NR

Median OS: NR

TRM: 16%

Knop et al. [125]. NDMM pts ≤60 y/o (w/ del 13)

199

ASCT × 2

CR: 31%

Median PFS: 23 mos

Median OS: 72 mos

2-year TRM: 4%

ASCT→RIC-Allo-SCT (Flu/Mel)

CR: 59%

Median PFS: 35 mos

Median OS: 70 mos

2-year TRM: 12%